Targeting the TGFβ signalling pathway in disease
By R. Akhurst, A. Hata. Nature reviews. Drug discovery, 2012
1,447 citations recorded by the source corpus.
Many drugs that target transforming growth factor-β (TGFβ) signalling have been developed, some of which have reached Phase III clinical trials for a number of disease applications. Preclinical and clinical studies indicate the utility of these agents in fibrosis and oncology, particularly in augmentation of existing cancer therapies, such as radiation and chemotherapy, as well as in tumour vaccines. There are also reports of specialized applications, such as the reduction of vascular symptoms of Marfan syndrome. Here, we consider why the TGFβ signalling pathway is a drug target, the potential clinical applications of TGFβ inhibition, the issues arising with anti-TGFβ therapy and how these might be tackled using personalized approaches to dosing, monitoring of biomarkers as well as brief and/or localized drug-dosing regimens.
Subfields: Genetics, Molecular Biology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/5f61973d01e92bb9ef20f85698c651b3cb2f6d20
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Cytokines in clinical cancer immunotherapy (2018, neutral): “Moreover, TGF-β decreases the activity of NK cells and CD8 T lymphocytes.(98) The relevance of the immunosuppressive activity of this cytokine in tumours has been conducive to the development of several small molecules, peptides, antisense oligonucleotides, cytokine traps and antibodies to block the”
- Fibroblast heterogeneity in the cancer wound (2014, background): “TGF- inhibitors are also capable of inhibiting cancer progression in animal models (Akhurst and Hata, 2012), but this pathway is highly context-dependent and complicated to target.”